|
May 29
|
Axsome Therapeutics to Participate in Upcoming Investor Conferences
|
|
May 28
|
Axsome Therapeutics Presents Data from Three of Its Innovative Neuroscience Programs at the American Society of Clinical Psychopharmacology (ASCP) 2025 Annual Meeting
|
|
May 27
|
Axsome Therapeutics Settles SUNOSI® (solriamfetol) Patent Litigation with Hetero Labs Ltd.
|
|
May 24
|
3 High-Flying Stocks That Could Soar Even More
|
|
Apr 10
|
Seeking Recession-Proof Stocks? RBC Suggests 2 Healthcare Stocks to Buy
|
|
Apr 8
|
Axsome Therapeutics to Report First Quarter 2025 Financial Results on May 5
|
|
Mar 14
|
Is Axsome Therapeutics, Inc. (AXSM) the Best Performing Growth Stock in 2025?
|
|
Feb 24
|
Axsome Therapeutics Full Year 2024 Earnings: EPS Misses Expectations
|
|
Feb 24
|
Axsome Says Symbravo Hits Primary Goal In Late-Stage Migraine Trial In Patients Experiencing Inadequate Response To Commonly Used Drugs
|
|
Feb 24
|
Axsome Therapeutics Announces SYMBRAVO® (meloxicam and rizatriptan) Achieves Primary Endpoint in the EMERGE Phase 3 Trial in Migraine Patients Experiencing Inadequate Response to Oral CGRP Inhibitors
|
|
Feb 23
|
Why Axsome Therapeutics, Inc. (AXSM) is the Best Performing Pharma Stock So Far in 2025
|
|
Feb 21
|
These Biotech Stocks Aren't Profitable But Still Make Elite IBD 50
|
|
Feb 19
|
Axsome Therapeutics, Inc. (AXSM): the Best Performing Healthcare Stock So Far in 2025
|
|
Feb 19
|
Axsome Therapeutics Inc (AXSM) Q4 2024 Earnings Call Highlights: Robust Revenue Growth Amid ...
|
|
Feb 19
|
Q4 2024 Axsome Therapeutics Inc Earnings Call
|
|
Feb 18
|
Axsome Therapeutics (AXSM) Q4 2024 Earnings Call Transcript
|
|
Feb 18
|
Axsome Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
|
|
Feb 16
|
This Stock Is Already Up by 55% in 2025: Is It Too Late to Buy?
|
|
Feb 11
|
Why Axsome Therapeutics (AXSM) Is Advancing Today
|
|
Feb 11
|
Why Axsome Therapeutics Stock Is Soaring Today
|